Status:
COMPLETED
Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC
Lead Sponsor:
Medical University of South Carolina
Conditions:
Solid Tumor, Adult
Eligibility:
All Genders
18+ years
Brief Summary
1. To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC. 2. To compare, in each patient, ctDNA longitudinal samples through t...
Detailed Description
The overall goal of this study is to study circulating tumor DNA (ctDNA) in the blood to determine how cancer cells in patients react to treatment. DNA is short for deoxyribonucleic acid. DNA contains...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of stage IV malignancy, including any advanced solid tumors (including lymphoma)
- Eastern Cooperative Oncology Group (ECOG) performance Status (PS) 0-3
- Life expectancy ≥ 3 months
- Patients must be able to provide consent
- Patients can be enrolled in other interventional clinical trials
Exclusion
- \- Age \< 18-year-old
Key Trial Info
Start Date :
October 12 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 6 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03302325
Start Date
October 12 2017
End Date
January 6 2020
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of South Carolina
Charleston, South Carolina, United States, 29425